These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36705879)

  • 21. STING activation in cancer immunotherapy.
    Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
    Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Oct; 25(19):e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization.
    Zhuo SH; Wang TY; Zhao L; Su JY; Hu JJ; Zhao YF; Li YM
    Angew Chem Int Ed Engl; 2024 Sep; 63(38):e202407037. PubMed ID: 38767062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
    Garland KM; Sheehy TL; Wilson JT
    Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
    Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
    Rivera Vargas T; Benoit-Lizon I; Apetoh L
    Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STING Signaling in Cancer Cells: Important or Not?
    Sokolowska O; Nowis D
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy.
    Zhou Q; Zhou Y; Li T; Ge Z
    Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle-Mediated STING Activation for Cancer Immunotherapy.
    Li Y; Li X; Yi J; Cao Y; Qin Z; Zhong Z; Yang W
    Adv Healthc Mater; 2023 Jul; 12(19):e2300260. PubMed ID: 36905358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists.
    Pan X; Zhang W; Guo H; Wang L; Wu H; Ding L; Yang B
    Biochem Pharmacol; 2023 Jul; 213():115596. PubMed ID: 37201875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STING Agonists as Cancer Therapeutics.
    Amouzegar A; Chelvanambi M; Filderman JN; Storkus WJ; Luke JJ
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING-mediated DNA sensing in cancer immunotherapy.
    Zhou X; Jiang Z
    Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles.
    Park KS; Xu C; Sun X; Louttit C; Moon JJ
    Adv Ther (Weinh); 2020 Oct; 3(10):. PubMed ID: 34295963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 39. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.
    Zheng J; Mo J; Zhu T; Zhuo W; Yi Y; Hu S; Yin J; Zhang W; Zhou H; Liu Z
    Mol Cancer; 2020 Aug; 19(1):133. PubMed ID: 32854711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING pathway agonism as a cancer therapeutic.
    Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
    Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.